Tag: booster

Categories
Health

Biden Officers Now Count on Weak People to Want Booster Pictures

Biden Officials Now Expect Vulnerable Americans to Need Booster Shots

WASHINGTON – Biden government health officials increasingly believe that vulnerable populations will need a booster dose even as research continues into how long coronavirus vaccines will remain effective.

Senior officials now say they believe that people over 65 or with compromised immune systems will most likely need a third vaccination from Pfizer-BioNTech or Moderna, two vaccines based on the same technology that were used to vaccinate the vast majority of Americans until now. That’s a significant shift from a few weeks ago when the government said there wasn’t enough evidence to support boosters.

On Thursday, a key official with the Centers for Disease Control and Prevention said the agency is looking into ways to give immune-compromised patients a third dose before regulators expand emergency approval for coronavirus vaccines, a move soon for Pfizer vaccination could be done.

Dr. Amanda Cohn, the chief medical officer of the CDC’s immunization division, told an agency advisory committee that officials are “actively seeking ways” to give certain people access to booster vaccinations “sooner than any possible change in government decisions”.

“So stay tuned,” she added.

The growing consensus within the government that at least some Americans need a booster dose is in part to do with research suggesting that the Pfizer vaccine is less effective against the coronavirus after about six months. More than half of those fully vaccinated in the United States to date have received Pfizer’s vaccine in two doses three weeks apart.

Pfizer’s ongoing global study of its clinical trial participants shows the vaccine’s effectiveness against symptomatic infections drops from a peak of 95 percent to 84 percent four to six months after the second dose, the company said.

Data from the Israeli government, which has fully vaccinated more than half of its population with doses of Pfizer since January, also suggests a downward trend in efficacy over time, though administrative officials view these data cautiously due to the large margin of error.

The latest figures from the Israeli Ministry of Health, released later this week, suggest that Pfizer’s vaccine was only 39 percent effective in preventing infections in the country in late June and early July, compared with 95 percent from January through April.

The vaccine remained more than 90 percent effective in preventing serious illnesses and almost as effective in preventing hospital stays. Israel began offering a third dose of Pfizer to citizens with severely compromised immune systems on July 12th.

Dr. Anthony S. Fauci, who heads the infectious diseases division of the National Institutes of Health, said he was surprised at the apparently steep drop in the effectiveness of the Pfizer vaccine suggested by the Israeli data. He said he wanted to compare it to data the CDC has collected from cohorts of thousands of people in the United States. “People raise their eyebrows a little,” he said.

While other questions abound, senior administrative officials said it was becoming increasingly clear that the vaccines would not provide unlimited immunity to the virus and that at least some people might need booster sessions nine months after their first vaccination. The government has already purchased more than enough vaccine to deliver the third dose of Pfizer and Moderna and has been quietly preparing to step up distribution efforts if necessary.

With so little data left public, many health officials and experts have spoken cautiously about booster vaccinations. Dr. Paul A. Offit, a member of the Food and Drug Administration’s external advisory committee of vaccine experts, said an increase in mild or moderate cases of Covid-19 in people who have been vaccinated does not necessarily mean that a booster is needed.

“The goal of this vaccine is not to prevent mild or mild, moderate infectious diseases,” he said. “The aim is to prevent hospitalization until death. At the moment this vaccine has withstood that. “

Updated

July 23, 2021, 10:06 p.m. ET

An early prospect of a third dose could also act as a deterrent against vaccination, warn other health experts. If Americans feel that immunity to the vaccines is short-lived, they are less likely to get their first vaccination.

“We don’t want people to believe that the vaccines are not effective when you talk about booster vaccinations,” said Dr. Fauci at a hearing before Congress on Tuesday. “You are highly effective.”

Among vaccine manufacturers, Pfizer has been particularly proactive in sharing its data with the government. But the government was stunned by the company’s public announcement earlier this month that it was planning to seek emergency FDA approval for a booster vaccination.

The company said early data from its booster study showed neutralizing antibody levels in clinical trial participants who received a third dose six months after the second was five to 10 times higher than those in recipients who received two doses.

Fearing that the American public would get the wrong news, the FDA and CDC responded with an unusual public statement: “Americans who have been fully vaccinated don’t need a booster right now.” They added, “We are prepared for booster doses, if and when science shows they are needed. “

Ordinarily, the FDA would approve the use of a booster, perhaps after a meeting of its external advisory committee. Then the CDC, which has its own advisory committee, would have to officially recommend it, said Dr. Offit.

Understand the state of vaccine mandates in the United States

But if the FDA fully licensed a vaccine, doctors would have much more leeway to prescribe a booster to their patients. Some health experts believe Pfizer could get this approval by fall this year.

At the CDC advisory board meeting on Thursday, Dr. Cohn, the medical director of the vaccines division, suggested that it might be possible to offer booster shots to people with compromised immune systems through a trial study or other means without waiting for the FDA

Dr. Camille Kotton, an infectious disease expert at Massachusetts General Hospital, told the panel that some patients, especially those who are more educated or “able to look after their own health care,” manage to get a third dose on their own, despite lack of green light from the government.

“Many took matters into their own hands,” she says. “I’m worried they might do this unattended,” she said, while the doctors’ hands are tied due to the lack of regulatory approval.

According to the CDC, people with a weakened immune system make up 2.7 percent of the population and include cancer, organ or stem cell transplants or HIV.

At the Senate Health Committee hearing Tuesday, several senators questioned administration health officials about how quickly they would act on the booster issue. Senator Mitt Romney, a Republican from Utah, said he was unhappy that officials couldn’t come up with a better schedule.

Senator Richard M. Burr, a Republican from North Carolina, noted that Israel is already offering a third chance to some of its most vulnerable citizens. “Why don’t we make the same decisions?” he asked.

Dr. Rochelle Walensky, the director of the CDC, testified that scientists studied the effectiveness of the vaccines in tens of thousands of people, including nursing home residents and more than 5,000 key workers.

“Fortunately, we expect this to wear off, not go down,” she said of her effectiveness. “As we see that fade, we will – this will be our time to act.”

Pfizer is expected to soon publish its clinical studies on immunity declining and the benefits of booster shoots in articles in a peer-reviewed journal. Moderna hasn’t released any data on booster studies, officials said.

Johnson & Johnson’s single-use vaccine has so far played a minor role in the country’s vaccination campaign. Clinical trial data on the mode of action of this two-shot vaccine is expected next month.

Noah Weiland contributed the reporting.

Categories
Health

Some portion of the U.S. inhabitants will get booster photographs, Dr. Scott Gottlieb says

Some portion of the U.S. population will get booster shots, Dr. Scott Gottlieb says

Former Commissioner of the Food and Drug Administration, Dr. Scott Gottlieb said Thursday that Covid booster vaccinations could become a reality for certain segments of the population. Gottlieb made the prediction, following the news, that a panel of expert advisors from the Centers for Disease Control and Prevention is planning to consider booster vaccinations for immunocompromised patients.

“I think the bottom line is that we will strengthen part of the population,” Gottlieb told CNBC’s “The News with Shepard Smith”. “I think it’s something we need to do to consider boosters, especially among the older, more vulnerable populations.”

Gottlieb noted that Israel already offers booster shots to adults with severe pre-existing conditions and that France and the UK are planning to give booster shots. The former FDA chief in the Trump administration also cited data from Israel showing that the shelf life of Covid vaccines does not last as long as researchers would have expected from the start.

“I think we will achieve our goal in terms of boosters, especially for the older population, who were vaccinated in December and January,” said Gottlieb. “You might get a very permanent reaction after the third dose.”

Host Shepard Smith also asked Gottlieb about the reintroduction of mask mandates across the country as a result of the highly transferable Delta variant. Los Angeles County issued a new mask mandate on Thursday that requires residents to wear masks indoors regardless of their vaccination status.

Gottlieb told Smith that he believed Los Angeles was the exception and advised individuals to take masking measures into their own hands.

“I think individuals in these hot spots across the country who are at risk need to take action and take precautions if they think they are at risk, as it is widespread in states that have already done so takes place affirmed that they will not return to mandates, “said Gottlieb.

Disclosure: Scott Gottlieb is a CNBC employee and a member of the board of directors of Pfizer, genetic testing startup Tempus, health technology company Aetion Inc., and biotechnology company Illumina.

Categories
Health

Dr. Anthony Fauci says speak of Covid booster photographs does not imply vaccines aren’t working

Dr. Anthony Fauci says talk of Covid booster shots doesn't mean vaccines aren't working

The Senior Medical Advisor to the White House, Dr. Anthony Fauci told CNBC on Tuesday that Covid booster vaccinations are currently unnecessary.

“The discussion about boosters is really adequate preparation on the part of the [drug] Company are working with the NIH and CDC and others to be prepared in the event you may need a boost, “Fauci said in the Squawk Box.

“But if you translate that into ‘We’re going to need a boost; everyone is going to get a boost’, that’s not appropriate. We still haven’t vaccinated enough people in the main part of it,” he added, emphasizing the booster discussion. ” has absolutely nothing to do with the effectiveness of the vaccine “.

With schools reopening in the fall and the spread of new coronavirus variants, questions are circulating about the need for booster vaccinations, even if the pace of primary vaccinations in the US has slowed since the spring.

On Monday, Pfizer officials met with federal health officials to advocate for the potential need for Covid boosters as the drug company prepares for US approval of a third dose of its current vaccine.

Pfizer announced last week that it is also developing a booster vaccine to combat the highly transmissible Delta variant – now the dominant strain of the virus in the US – and said the immunity was boosted by its Two, developed with German partner BioNTech Shot vaccine wears off.

However, the Centers for Disease Control and Prevention and the Food and Drug Administration released a joint statement blaming Pfizer’s insistence on a third dose, saying that fully vaccinated Americans do not currently need a booster dose.

The officials’ conversation with Pfizer was mostly “a courtesy meeting,” Fauci, director of the National Institute of Allergies and Infectious Diseases, also told CNBC on Tuesday. He said the real question right now is how long protection against the vaccines will last and at what level of protection, a view shared by other health experts.

Former Obama administration official, Dr. Kavita Patel told CNBC on Monday ahead of the Pfizer meeting that booster shots seem like “inevitable” due to newer variations, but questioned when it will happen. She also stressed that when discussing boosters in the US, it is important to take into account the global impact on vaccine adoption in other parts of the world.

Dr. Ashish Jha, dean of Brown University’s School of Public Health, told CNBC on Friday that he had “seen no evidence yet of anyone needing a third injection”.

According to CDC data, the majority of Americans were vaccinated with Pfizer, followed by the two-shot Moderna vaccine and Johnson & Johnson’s single-shot course. More than 184 million people in the United States, or 55.5% of the population, have had at least one injection. Almost 160 million people, or 48% of the population, are fully vaccinated.

Fauci also told CNBC on Tuesday that he would be “amazed” if Pfizer, Moderna and J & J’s coronavirus vaccines don’t get full approval from US drug regulators. These three vaccines are the only ones approved by the FDA in the United States, and they were approved for emergency approval.

Categories
Health

Dr. Kavita Patel says want for a Covid booster shot appears inevitable

Dr. Kavita Patel says need for a Covid booster shot seems inevitable

Former Obama administration official Dr. Kavita Patel told CNBC on Monday that she expected a Covid vaccine booster to eventually be approved by U.S. regulators due to new, more transmissible variants of coronavirus.

“With the threat of the Delta variant and possibly other looming variants in the future, it seems inevitable that we will need a booster shot,” Patel said on Squawk Box. “But that trillion dollar question is when? It seems like six months is early.”

The comments from Patel, who now works as a family doctor in Washington, came before Pfizer representatives met with federal health officials on Monday to discuss the possible need for Covid booster vaccinations.

Pfizer recently said it is developing a booster shot to combat the highly transmissible Delta variant. In that announcement, the drug maker cited internal data and a study in Israel showing that six months after vaccination, people experience decreased immunity from Pfizer’s two-dose vaccine as Delta becomes the predominant variant in the country.

The company said a third dose of its existing vaccine could help boost immunity. Over the past few months, executives at Pfizer and its German partner BioNTech have said that people will likely need a third dose of vaccine within a year of being fully vaccinated.

However, shortly after Pfizer’s announcement last week, the Centers for Disease Control and Prevention and the Food and Drug Administration released a joint statement stating that fully vaccinated Americans do not currently need a booster vaccination.

This view is supported by health experts like Dr. Ashish Jha, dean of Brown University’s School of Public Health, shared. Jha told CNBC on Friday that he had “seen no evidence yet that anyone needs a third shot”.

While Patel said the data suggests that all three of the Covid vaccines currently approved in the US – the two-dose Pfizer and Moderna vaccines and the Johnson & Johnson single-dose vaccine – offer “more than enough immunity” To protect against severe hospitalization and death, Pfizer did not criticize Pfizer for working on the booster intake.

“I think what we do know is that, even six months ago, immunity declines over time. The question is, how long? ”Said Patel, who served as policy director for the Bureau of Interstate Affairs and Public Engagement in the Obama administration.

People shouldn’t get a third vaccination now, Patel warned.

“We have seen patients who did this accidentally or even deliberately, and they had even more dramatic side effects than the second shot, so I wouldn’t encourage anyone,” said Patel.

Finally, if a booster is recommended by regulators, people should expect the CDC to make recommendations for specific populations, similar to what happened when the vaccine was initially introduced with a focus on high-risk groups. “It won’t come one, it will all,” she said.

Patel said the conversation about booster shots in the US must take into account the global impact, given the difficult introduction in other parts of the world.

“It won’t help the United States if the rest of the world stays unvaccinated and they have the opportunity to get hundreds of millions of doses because we got a booster,” said Patel.

Categories
Health

U.S. Officers Push Again on Pfizer’s Request for Booster Shot Approval

U.S. Officials Push Back on Pfizer’s Request for Booster Shot Approval

Pfizer officials met privately with senior U.S. scientists and regulators on Monday to press for rapid approval of booster coronavirus vaccines amid growing public confusion over whether they are needed and opposition from federal health officials who say that the additional doses are now not required.

The high-level online meeting, which lasted an hour, and at which Pfizer’s chief scientist briefed virtually every top doctor in the federal government, took place the same day Israel began feeding heart transplant patients and others on the third dose of the Pfizer BioNTech vaccine administer weakened immune system. Officials said after the meeting that more data – and possibly several months – would be needed before regulators could determine whether booster injections were needed.

The two developments underscored the intensifying debate about whether booster injections are required in the US, when and for whom. Many American experts, including Dr. Anthony S. Fauci, President Biden’s senior medical advisor on the pandemic, have said there isn’t enough evidence yet that boosters are necessary. However, some say Israel’s move may anticipate a government decision to recommend it to at least the weak.

Pfizer is collecting information on antibody responses from those receiving a third dose, as well as data from Israel, and expects to share at least part of that in a formal application to the Food and Drug Administration for its coronavirus vaccine to expand its emergency clearance in the coming weeks.

However, the final decision on booster vaccination, several officials said after the meeting, will also depend on real-world information the Centers for Disease Control and Prevention has gathered about breakthrough infections – those that occur in people who have been vaccinated – who are serious or ill Cause hospital stays.

And any booster vaccination recommendations are likely to be calibrated within age groups as well, officials said. For example, if booster shots are recommended, they could first go to residents of nursing homes who received their vaccines in late 2020 or early 2021, while older people who received their first vaccinations in the spring may have to wait longer. And then the question arises, what kind of booster: a third dose of the original vaccine or perhaps a vaccination tailored to the highly contagious Delta variant, which is on the rise in the USA.

“It was an interesting meeting. They shared their data. There was nothing like a decision, ”said Dr. Fauci in a short interview Monday night, adding, “This is just part of a much bigger puzzle, and it’s part of the data, so there’s no question of a compelling case either way.”

Amy Rose, a Pfizer spokeswoman, said in a statement, “We had a productive meeting with US public health officials about elements of our research program and preliminary booster data.”

The Ministry of Health and Welfare, which convened the meeting, issued its own statement confirming the government’s stance. “At this point, fully vaccinated Americans don’t need a booster dose,” it said.

With less than half of the United States’ population being fully vaccinated, some experts said Monday the country must continue to focus on giving all Americans their first dose. The most important task of the Food and Drug Administration is to increase public confidence by granting full approval to the coronavirus vaccines used, which are initially approved in an emergency.

“At this point the most important strengthening we need is vaccinating people,” said Dr. Carlos del Rio, an infectious disease expert at Emory University in Atlanta. The booster doses in Israel, he added, “will help us answer some questions, but at the end of the day I disagree with what they are doing. I think it’s terribly premature. “

Within the Biden government, some fear that if Americans are convinced that coronavirus vaccines only offer short-lived immunity before needing a boost, they are less likely to accept vaccination. Those concerns could fall by the wayside, however, if new data from Israel, expected in the next few weeks, conclusively shows that immunity wears off after six to eight months, significantly increasing the risks for the elderly or other vulnerable populations.

The government convened the meeting on Monday in response to the announcement last week by Pfizer and its German partner BioNTech that they would develop a version of their vaccine targeting the Delta variant and reported promising results from studies with people who A third dose of the vaccine received original vaccine six months after the second.

The new dates Not yet published or peer-reviewed, but as announced by companies that they would submit data to the Food and Drug Administration to approve booster vaccinations surprised the Biden White House.

In an unusual joint statement Thursday evening, hours after Pfizer-BioNTech’s announcement, the FDA and CDC pushed back.

“Americans who are fully vaccinated currently do not need a booster,” the statement said, adding, “We are prepared for booster doses when and when science shows they are needed.”

The move can make economic sense for Pfizer-BioNTech. Since the outbreak of the pandemic, the partner companies have been following a “get to market first” strategy in the manufacture and marketing of their vaccines.

The companies did not accept federal funds or participate in Operation Warp Speed, former President Donald J. Trump’s fast-track vaccine initiative. Not only were they the first to get Food and Drug Administration approval for their coronavirus vaccine, the first to use the novel mRNA technology, but also the first to get their vaccine approved in adolescents.

The strategy has “paid off as well as you could wish,” said Steve Brozak, president of WBB Securities, a biotechnology-focused research investment bank.

Last week, Pfizer and BioNTech said a booster given six months after the second dose of the vaccine increased the effectiveness of antibodies against the original virus and beta variant by five to ten times. But antibody levels may not be the best biological measure of need for booster doses, say experts, who say it’s no surprise that antibodies increase after a third dose.

“The antibody response is not the only measure of immune protection,” said Dr. Leana S. Wen, a former health commissioner for Baltimore. “There have been several studies to suggest that these vaccines also stimulate B-cell and T-cell immunity. Even if there aren’t that many antibodies, it doesn’t mean someone isn’t protected. “

In Israel, the government has agreed to provide Pfizer with data on its vaccine recipients, and Pfizer has cross-checked the Israeli data with the results of its own laboratory tests. Some people familiar with the data say this suggests that those vaccinated may lose immunity after about six to eight months, leading to an increasing number of breakthrough infections.

The participants in Monday’s meeting were a who’s who of government doctors: Dr. Fauci; Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention; Dr. Francis Collins, the director of the National Institutes of Health; Dr. Vivek Murthy, the general surgeon; Dr. Rachel Levine, the assistant secretary of health; Dr. Janet Woodcock, acting FDA commissioner; Dr. Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research; and Dr. David Kessler, a former FDA commissioner who, among other things, leads the Biden government’s vaccine distribution efforts.

Dr. Del Rio, of Emory University, complained that the meeting was held privately on Monday instead of Pfizer publicly presenting its dates to the CDC’s Advisory Committee on Vaccine Practices, which will ultimately recommend whether booster injections are needed.

Just over two-thirds of American adults – 67.7 percent – got at least one Covid-19 shot, according to the CDC. The president had hoped to have at least partially vaccinated 70 percent of adults by July 4th.

Still, the national vaccination campaign has made it clear that the vaccine is successful in preventing disease, and studies suggest that vaccines against the Delta variant remain effective. Outbreaks occur in areas with low vaccination rates and the number of national cases has increased recently; according to a database from the New York Times.

World Health Organization officials on Monday stressed the importance of prioritizing global vaccine production and distribution over booster development, given the large gaps between countries’ vaccine programs.

“That doesn’t mean one or the other; it brings order to a crisis, ”said Dr. Michael Ryan, the organisation’s executive director of the emergency health program, on what the organization calls a two-stage pandemic.

Lauren McCarthy contributed to the coverage.

Categories
Health

Citing the Delta Variant, Pfizer Will Pursue Booster Pictures and a New Vaccine

Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine

Pfizer and BioNTech announced Thursday that they are developing a version of the coronavirus vaccine that will target Delta, a highly contagious variant that has spread to nearly 100 countries. The companies expect to begin clinical trials of the vaccine in August.

Pfizer and BioNTech also reported promising results from studies of people who received a third dose of the original vaccine. A booster shot six months after the second dose of the vaccine increases the effectiveness of the antibodies against the original virus and beta variant by five to ten-fold, the companies say.

The vaccine’s effectiveness could decline six months after immunization, the companies said in a press release, and booster doses may be needed to fight off virus variants.

The data were neither published nor peer-reviewed. The vaccine manufacturers said they expected to submit their results to the Food and Drug Administration in the coming weeks, a step toward approval for booster shots.

But the companies’ claims contradict other research, and several experts dismissed the claim that boosters are needed.

“Given the variants currently circulating, there is really no evidence of a third booster or a third dose of an mRNA vaccine,” said Dr. Celine Gounder, an infectious disease specialist at Bellevue Hospital Center in New York. “In fact, many of us wonder if you’ll ever need boosters.”

Federal authorities also sounded dubious on Thursday night. In general, Americans who have been fully vaccinated currently do not need a booster vaccination, the FDA and the Centers for Disease Control and Prevention said in a joint statement.

“We are prepared for booster doses when science shows they are needed,” the authorities said.

The Delta variant, first identified in India, is believed to be about 60 percent more contagious than Alpha, the version of the virus that ripped through the UK and much of Europe earlier this year, and perhaps twice as contagious as the original coronavirus.

The delta variant is now causing outbreaks among unvaccinated populations in countries like Malaysia, Portugal, Indonesia and Australia. In the USA, too, Delta is now the dominant variant, the CDC reported this week.

Until recently, infections in the US were at their lowest level since the pandemic began. Hospital stays and deaths related to the virus have continued to decline, but new infections could increase.

It is not yet clear to what extent the variant is responsible for this; A slower vaccination campaign and quick reopenings also play a role.

Citing data from Israel, Pfizer and BioNTech suggest that the effectiveness of their vaccine “in preventing infections and symptomatic illnesses decreased six months after vaccination.” Given the surge in Delta and other variants, the companies said “a third dose may be required within 6 to 12 months of full vaccination”.

Updated

July 11, 2021 at 1:57 p.m. ET

Health officials in Israel have estimated that full vaccination with the Pfizer BioNTech is only 64 percent effective against the Delta variant. (It is more than 90 percent effective against the original virus.)

But Israel’s estimates have been disproved by a number of other studies which found the vaccine to be very effective at preventing infection – against all variants. For example, a recent study showed that mRNA vaccines like those from Pfizer trigger a sustained immune response in the body that can protect against the coronavirus for years.

“Pfizer is looking opportunistic by putting an announcement on the back of very early and undigested data from Israel,” said John Moore, a virologist at Weill Cornell Medicine in New York. “When the time comes to use boosters here, the decision is not up to you.”

The companies described their plan to develop a new vaccine against Delta as a kind of backup measure in case the original vaccine replenishment fails. The new vaccine targets all of the spike protein, not a portion, and the first batch has already been made.

The delta variant poses challenges for the immune system. In the journal Nature on Thursday, French researchers reported new evidence that the delta variant can partially bypass the body’s immune response, as changes to the spike protein on its surface make it difficult for antibodies to attack.

The team analyzed blood samples from 59 people after they received the first and second doses of the vaccine. Blood samples from just 10 percent of those immunized with a dose of the AstraZeneca or Pfizer-BioNTech vaccines were able to neutralize the Delta and Beta variants in laboratory tests.

“A single dose of Pfizer or AstraZeneca was either poorly effective or not effective at all against beta and delta variants,” the researchers concluded. Data from Israel and the UK largely support this finding, although those studies also suggested that one dose of vaccine was still enough to prevent hospitalization or death from the virus.

But a second dose increased the effectiveness to 95 percent. There was not much difference in the levels of antibodies produced by the two vaccines.

“When you receive two doses of an mRNA vaccine, you are very well protected against serious illness, hospitalization and death for each of the variants,” said Dr. Gounder.

The researchers also looked at blood samples from 103 people infected with the coronavirus. Delta was much less sensitive than Alpha to samples from unvaccinated individuals in this group, the study found.

One dose of vaccine increased sensitivity significantly, suggesting that people who have recovered from Covid-19 may still need to be vaccinated to fight off some variants.

Taken together, the results suggest that two doses of the vaccine provide strong protection against all variants, as does one dose for people who have recovered from Covid-19 and have some natural immunity.

Some experts also questioned discussions about boosters for Americans while much of the world has not yet received a single dose.

“It’s impossible to ignore the global situation,” said Natalie Dean, biostatistician at Emory University in Atlanta. “I find it hard to imagine getting a third dose when there are front line workers treating Covid patients who have not yet been vaccinated.”

Every unvaccinated person offers the virus additional opportunities to mutate into dangerous variants, said Dr. Gounder feast.

“If we are concerned about variants,” she said, “our best protection is to get the rest of the world vaccinated, and not to hoard more doses to give people here in the US third doses of mRNA vaccines. “

Categories
Health

No proof a booster shot is required, says Dr. Ashish Jha

No evidence a booster shot is needed, says Dr. Ashish Jha

Covid booster doses are currently not required, said the dean of the School of Public Health at Brown University on Friday, as highly transmissible new variants test the protection of available vaccines.

“Let me tell you where we are: the data is very clear, if you got your two shots from Moderna or Pfizer or a single shot from J&J you have a very high level of protection against all variants, including Delta” said Dr. Ashish Jha. “I haven’t seen any evidence yet that anyone needs a third shot.”

Jha’s comments come after Pfizer and BioNTech announced Thursday that they are developing a Covid-19 booster shot that will target the Delta variant. Company officials say another vaccination may be needed as immunity to the vaccine appears to decline over time.

In CNBC’s The News with Shepard Smith, Jha emphasized the importance of waiting for the dates when it comes to a booster shot.

“When this evidence comes along, and of course we will want to take that into account, I think I think it is unlikely that we will need third shots for most people,” Jha said.

The Centers for Disease Control and Prevention and the Food and Drug Administration issued a joint statement stating that Americans who are fully vaccinated do not need a booster vaccination.

“Americans who have been fully vaccinated currently do not need a booster vaccination. FDA, CDC, and [the National Institutes of Health] are involved in a science-based, rigorous process to check if or when a refresher might be needed, “said a joint statement released Thursday evening.

Categories
Health

Pfizer says it’s growing a Covid booster shot to focus on the extremely transmissible delta variant

Pfizer says it is developing a Covid booster shot to target the highly transmissible delta variant

Pfizer and BioNTech announced Thursday that they are developing a Covid-19 booster vaccine that will target the Delta variant amid concerns about the highly communicable strain that is already the predominant form of the disease in the United States.

The companies said that while they believe a third vaccination of their current two-dose vaccine has the potential to maintain the “highest level of protection” against all currently known variants, including Delta, they are “vigilant” and are developing an updated version of the Vaccine.

“As evidenced by real evidence from the Israeli Ministry of Health, the effectiveness of the vaccine has declined six months after vaccination, while at the same time the Delta variant is becoming the dominant variant in the country,” the companies said in a written statement.

“These results are consistent with an ongoing analysis of the companies’ Phase 3 study,” they said. “This is why we have said, and continue to believe, that all of the data we have, it is likely that a third dose may be required within 6 to 12 months of full vaccination.”

Clinical trials could begin as early as August, subject to regulatory approvals, the companies said.

The announcement comes on the same day the Olympic Games organizers said they would be banning all viewers from the Games this year after Japan declared a state of emergency designed to stem a wave of new Covid-19 infections that are partly due to the Delta variant is due.

Delta is estimated by the World Health Organization to be about 55% more transmissible than Alpha, the variant first found in the UK that once dominated the US, didn’t do as well at protecting against mild illnesses and the spread of the disease to others, scientists say.

On Monday, Israeli officials reported a decrease in the effectiveness of the Pfizer BioNTech vaccine in preventing infections and symptomatic diseases, but said it remained highly effective in preventing serious diseases.

In the US, health officials are urging all eligible Americans to get vaccinated as soon as possible, especially before the fall season when Delta is expected to lead to a further surge in new coronavirus cases, especially in places with the lowest vaccination rates.

There are about 1,000 counties in the U.S. with a Covid vaccination rate of less than 30%, mostly located in the Southeast and Midwest, said CDC Director Dr. Rochelle Walensky recently. In these areas, the authority already sees increasing infection rates due to the further spread of the delta variant.

Pfizer and BioNtech executives have repeatedly said that people will likely need a booster vaccination or a third dose within 12 months of full vaccination, as they expect vaccine-induced immunity to wear off over time. They also said that people are likely to have to take extra shots every year.

Pfizer and BioNTech are developing booster vaccines and are expected to apply for US approval for a third dose of their vaccine shortly.

Categories
Health

CDC group says there is not sufficient information but to suggest booster pictures

CDC group says there isn't enough data yet to recommend booster shots

A group of Centers for Disease Control and Prevention scientists said Wednesday that currently there isn’t enough data to support recommending Covid-19 booster shots to the general population but that more-vulnerable groups, such as elderly people or transplant recipients, may need an extra dose.

The Covid-19 working group of the CDC’s Advisory Committee on Immunization Practices didn’t rule out the possibility that the general population eventually may need booster shots if immunity from the vaccines wanes or a variant reduces the effectiveness of current shots.

“Boosters may be required for a broad population. However, it could also be that the need for boosters of Covid vaccine may only be demonstrated in some populations,” said Dr. Sarah Oliver, co-lead of the working group and a medical epidemiologist with the CDC’s National Center for Immunization and Respiratory Diseases.

A recent study by researchers at Johns Hopkins University published in the Annals of Internal Medicine showed that booster shots may be beneficial for people with weakened immune systems. Oliver said the agency should monitor residents of long-term care facilities, elderly people, health-care workers and immunocompromised people.

The working group recommended that the CDC consider booster shots only “after evidence of declining protection,” Oliver said, meaning if the vaccines became less effective over time or antibodies guarding against Covid waned over time. The agency could also consider using booster shots if a variant emerged that substantially reduced the effectiveness of the vaccine.

Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.

Dado Ruvic | Reuters

“I would have to agree with the interpretation of the working group in the sense that there’s no data to support recommendations to support boosters at this time,” said Dr. Sharon Frey, a member of ACIP and clinical director of the Center for Vaccine Development at Saint Louis University Medical School. “There’s no evidence against declining protection at this time.”

But Frey said she would be open to giving a third shot to transplant patients or if infections rise in the general population, indicating a lot of breakthrough cases in fully vaccinated individuals. So far, there have been at least 3,729 breakthrough infections in the U.S. that resulted in hospitalization or death, according to CDC data.

“I think the only thing we can do at this moment is, if we start to see an uptick in reinfection in people or new infections in people who have been vaccinated, that’s our clue that we need to move quickly,” Frey said.

Dr. Grace Lee, who chairs the ACIP safety group and is a professor of pediatrics at Stanford University School of Medicine, also said she would like to see more evidence of breakthrough cases before recommending a booster shot.

“I would want greater certainty on the safety data if we’re talking about boosting before it’s clear what the risk data will look like,” Lee said. “If we’re seeing severe breakthrough cases then I think the decision-making moves forward even if there’s uncertainty with the safety data.”

Categories
Health

We’ll In all probability Want Booster Photographs for Covid-19. However When? And Which Ones?

We’ll Probably Need Booster Shots for Covid-19. But When? And Which Ones?

As the nation moves closer to President Biden’s goal of 70 percent vaccination rates, many people wonder how long their protection will last.

Right now, scientists are asking a lot of questions about Covid-19 booster vaccinations, but they don’t have many answers yet. The National Institutes of Health recently announced that they have started a new clinical trial of fully vaccinated people – with an approved vaccine – to see if a booster of the Moderna syringe increases their antibodies and protects against infection with the virus extended.

Although many scientists estimate that the US-approved vaccines Pfizer-BioNTech, Moderna, and Johnson & Johnson will last at least a year, no one knows exactly. It is also unclear whether emerging variants of the coronavirus will change our vaccination needs.

“We’re breaking new ground here when it comes to boosters,” said Dr. Edward Belongia, a physician and epidemiologist at the Marshfield Clinic Research Institute in Marshfield, Wisconsin.

Different pathogens affect our immune system in different ways. With some diseases, such as measles, a one-time illness leads to lifelong protection against further infection. But with other pathogens, our immune defense declines over time.

In some important ways, vaccines mimic natural infections – without actually getting sick. Measles vaccines can induce lifelong immunity. Tetanus vaccines, on the other hand, create defenses that fade year after year. The Centers for Disease Control and Prevention recommends getting a tetanus booster once every decade.

And sometimes the virus can change itself, so a booster is needed to create a new, bespoke defense. Influenza viruses are so changeable that they need a new vaccine every year.

The short answer is that we can’t be sure yet because people were vaccinated in large numbers just a few months ago.

“Even in the studies, we don’t know what the immune response is like a year later,” said Dr. Kirsten Lyke, vaccine expert at the University of Maryland School of Medicine and director of the NIH booster study.

But the first signs are encouraging. In vaccine trials, researchers have drawn blood from volunteers and measured their levels of antibodies and immune cells that target the coronavirus. The levels are going down, but gradually. It is possible that with this slow decline, vaccination protection will remain strong for a long time. People who were previously infected and then received the vaccine can enjoy even more permanent protection.

“I think there is a real possibility that immunity to the original strain could last for years,” said Dr. Belongia.

If this possibility is confirmed, Covid-19 boosters may not be required for years. But that’s a big if.

Possibly. Scientists have already established that vaccines with different technologies can vary in their effectiveness. The most powerful vaccines include Moderna and Pfizer-BioNTech, both of which are based on RNA molecules. Inactivated virus-based vaccines, such as those from Sinopharm in China and Bharat Biotech in India, have proven to be slightly less effective.

It’s not entirely clear why that is, said Scott Hensley, an immunologist at the University of Pennsylvania. RNA vaccines are relatively new and so the immunity they induce has not been thoroughly studied. In his own research on mice given different types of flu vaccines – some with RNA and others with inactivated viruses – Dr. Hensley made a similar difference. The amount of antibodies produced by the two vaccines was “grossly different,” he said.

It is possible that protection from the less effective Covid-19 vaccines may wear off faster. Sinopharm’s vaccine may already show signs of this decline. Clinical studies show an effectiveness of 78 percent. But the United Arab Emirates and Bahrain are already offering boosters to people who have received the Sinopharm vaccine to boost their declining immunity.

Scientists are looking for biological markers that could show when protection from a vaccine is no longer sufficient to hold back the coronavirus. It is possible that a certain level of antibody marks a threshold: if your blood is above this level you are in good shape, but if you are below you are at greater risk of infection.

Some preliminary studies suggest that these markers – known as correlates of protection – exist for Covid-19 vaccines. Research is being carried out to find them.

Updated

June 6, 2021, 2:38 p.m. ET

“That will teach us a lot,” says Dr. H. Clifford Lane, Associate Director, Clinical Research and Special Projects, National Institute of Allergy and Infectious Diseases.

We may need boosters to block variants, but that’s not yet clear.

The emergence of variants in recent months has accelerated research on boosters. Some variants have mutations that caused them to spread quickly. Others carry mutations that could affect the effectiveness of approved vaccines. But at this point in time, scientists have little evidence of how existing vaccines work against different variants.

Last month, for example, researchers in Qatar published a study of the Pfizer BioNTech vaccine, which was given to over a quarter of a million of the country’s residents between December and March.

Clinical studies showed that the vaccine was 95 percent effective against the original version of the coronavirus. But a variant called Alpha, which was first identified in the UK, cut its effectiveness to 89.5 percent. A variant first identified in South Africa, known as Beta, further reduced the vaccine’s effectiveness to 75 percent. However, against both variants, the vaccine was 100 percent effective in preventing serious, critical, or fatal illnesses.

Just because a variant can bypass existing vaccines doesn’t mean it becomes a widespread problem. Beta, for example, has remained rare in countries with strong vaccine programs like Israel, the UK, and the United States. If beta stays infrequent, it doesn’t pose a serious threat.

But evolution still has a lot of leeway to play with the coronavirus. Scientists cannot rule out the possibility that new variants will emerge in the coming months that will spread quickly and resist vaccines.

“It is clear that variants are inevitable,” said Dr. Grace Lee, Associate Chief Medical Officer, Practice Innovation and Infectious Disease Doctor at Stanford Children’s Health. “I think the question is how effective are they going to be?”

Its not clear yet. Some scientists suspect that a high immune response to the original version of the coronavirus also provides adequate protection against variants. But it is also possible that a vaccine that specifically thwarted one variant might be more effective.

Pfizer has made an attempt to test both options. Some volunteers who have already received two doses of their vaccine will be given a third dose of the same vaccination as a booster. In the same study, the researchers will give other volunteers an experimental booster designed to protect against the beta variant.

“Based on what we’ve learned so far, we currently think that until we see a decrease in SARS-CoV-2 circulation and Covid-19 disease, we think it likely that a third dose, a Increasing our vaccine, within 12 months of vaccine administration, will likely be needed to protect against Covid-19, “said Jerica Pitts, director of global media relations at Pfizer.

Possibly. In fact, much research on other diseases suggests that switching vaccines may increase the booster dose. “This is a proven concept from before Covid,” said Dr. Lyke.

Dr. Lyke and her colleagues are testing this mix-and-match option for boosters as part of their new study. They are recruiting volunteers who have been fully vaccinated with any of three US approved vaccines – Johnson & Johnson, Moderna, and Pfizer-BioNTech.

All volunteers receive a Moderna booster. The researchers will then observe how strong an immune response it creates.

It is possible that other vaccines that are still in clinical trials may work even better as Covid boosters. For example, Novavax and Sanofi are both conducting clinical trials of vaccines made from viral proteins in the United States. Dr. Lyke and her colleagues designed their study so that they could add more such vaccines later.

“We are working behind the scenes on other contracts so we can bring additional boosters into the study,” she said. These additional boosters can also include those tailored to variants, such as the one developed by Pfizer-BioNTech.

Other mixed booster studies are also ongoing. In the UK, scientists are giving volunteers vaccines from AstraZeneca, CureVac, Johnson & Johnson, Moderna, Novavax, Pfizer-BioNTech and Valneva as boosters. ImmunityBio is testing its vaccine in South Africa as a booster for the Johnson & Johnson vaccine, while Sanofi prepares to test its vaccine as a booster for those of several other companies.

The NIH study could start delivering results as early as the next few weeks. If fading vaccines and rising variants lead to an outbreak of new infections this winter, Dr. Lyke have data to share with policy makers.

“It was vital for us to get a response as soon as possible,” she said. “We just don’t have this luxury of time.”

Dr. Hensley says it is wise to prepare for the possibility that boosters will be needed. But he hoped they didn’t detract from the urgent need to give billions of people around the world first doses.

“If more people are protected immediately, the virus will have fewer hosts to infect and fewer opportunities to develop into new variants,” he said.

“I want these vaccines to go global because I want to protect people all over the world,” added Dr. Hensley added. “But even if you only take care of yourself, you should also stand behind these efforts, because this is the only way to end the pandemic and limit the development of variants.”

Noah Weiland contributed the reporting.